Cargando…

(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma

BACKGROUND: Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Regelink, J. C., Raijmakers, P. G., Bravenboer, N., Milek, R., Hoetjes, N. J., de Kreuk, A. M., van Duin, M., Wondergem, M. J., Lips, P., Sonneveld, P., Zijlstra, J. M., Zweegman, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887457/
https://www.ncbi.nlm.nih.gov/pubmed/27246327
http://dx.doi.org/10.1186/s13550-016-0197-4
_version_ 1782434727637024768
author Regelink, J. C.
Raijmakers, P. G.
Bravenboer, N.
Milek, R.
Hoetjes, N. J.
de Kreuk, A. M.
van Duin, M.
Wondergem, M. J.
Lips, P.
Sonneveld, P.
Zijlstra, J. M.
Zweegman, S.
author_facet Regelink, J. C.
Raijmakers, P. G.
Bravenboer, N.
Milek, R.
Hoetjes, N. J.
de Kreuk, A. M.
van Duin, M.
Wondergem, M. J.
Lips, P.
Sonneveld, P.
Zijlstra, J. M.
Zweegman, S.
author_sort Regelink, J. C.
collection PubMed
description BACKGROUND: Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients. METHODS: Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of (18)F-uptake. RESULTS: The inter- and intra-individual variations in (18)F-uptake (SUV(A50%)) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and (18)F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from −2.20 to 4.53. CONCLUSIONS: Iliac (18)F-uptake was associated with the local MAR in myeloma patients. Furthermore, (18)F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-016-0197-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4887457
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-48874572016-06-17 (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma Regelink, J. C. Raijmakers, P. G. Bravenboer, N. Milek, R. Hoetjes, N. J. de Kreuk, A. M. van Duin, M. Wondergem, M. J. Lips, P. Sonneveld, P. Zijlstra, J. M. Zweegman, S. EJNMMI Res Preliminary Research BACKGROUND: Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients. METHODS: Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of (18)F-uptake. RESULTS: The inter- and intra-individual variations in (18)F-uptake (SUV(A50%)) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and (18)F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from −2.20 to 4.53. CONCLUSIONS: Iliac (18)F-uptake was associated with the local MAR in myeloma patients. Furthermore, (18)F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-016-0197-4) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-05-31 /pmc/articles/PMC4887457/ /pubmed/27246327 http://dx.doi.org/10.1186/s13550-016-0197-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Preliminary Research
Regelink, J. C.
Raijmakers, P. G.
Bravenboer, N.
Milek, R.
Hoetjes, N. J.
de Kreuk, A. M.
van Duin, M.
Wondergem, M. J.
Lips, P.
Sonneveld, P.
Zijlstra, J. M.
Zweegman, S.
(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma
title (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma
title_full (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma
title_fullStr (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma
title_full_unstemmed (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma
title_short (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma
title_sort (18)f-fluoride-pet for dynamic in vivo monitoring of bone formation in multiple myeloma
topic Preliminary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887457/
https://www.ncbi.nlm.nih.gov/pubmed/27246327
http://dx.doi.org/10.1186/s13550-016-0197-4
work_keys_str_mv AT regelinkjc 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT raijmakerspg 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT bravenboern 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT milekr 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT hoetjesnj 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT dekreukam 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT vanduinm 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT wondergemmj 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT lipsp 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT sonneveldp 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT zijlstrajm 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma
AT zweegmans 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma